TherapeuticsMD (TXMD) Short term Debt (2011 - 2022)
TherapeuticsMD's (TXMD) quarterly Short term Debt came in at $93.6 million in Q3 2022, up 524.01% on a YoY basis from $15.0 million in Q3 2021, and up 3.11% quarter-over-quarter from $90.8 million in Q2 2022.
Powered by 
Analysis
TherapeuticsMD (TXMD) Short term Debt (2011 - 2022) Analysis & Trends
TherapeuticsMD (TXMD) has reported Short term Debt for 4 consecutive years, with $93.6 million the latest figure, recorded in Q3 2022.
- For the quarter ending Q3 2022, Short term Debt rose 524.01% year-over-year to $93.6 million; the trailing twelve-month figure through Sep 2022 stood at $93.6 million (up 524.01% YoY), and the FY2021 full-year result was $188.3 million, changed N/A from the prior year.
- Short term Debt advanced to $93.6 million in Q3 2022 per TXMD's latest filing, from $90.8 million in the prior quarter.
- Across five years, Short term Debt topped out at $202.9 million in Q1 2022 and bottomed at $5.0 million in Q1 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 650.65 Bn | 629.89 Bn | 17.26 Bn |
| 2 | AbbVie | 466.34 Bn | 459.82 Bn | 12.70 Bn |
| 3 | Merck | 362.11 Bn | 355.02 Bn | 12.21 Bn |
| 4 | Novartis Ag | 267.81 Bn | 260.52 Bn | 11.24 Bn |
| 5 | Pfizer | 157.31 Bn | 145.91 Bn | 10.94 Bn |
| 6 | Bristol Myers Squibb | 128.75 Bn | 117.69 Bn | 9.25 Bn |
| 7 | Sanofi | 51.80 Bn | 44.84 Bn | 10.79 Bn |
| 8 | Revolution Medicines | 40.91 Bn | 40.91 Bn | - |
| 9 | BeOne Medicines | 39.65 Bn | 34.55 Bn | 1.53 Bn |
| 10 | TherapeuticsMD | 25.35 Mn | 16.16 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2022 | 93.60 Mn |
| Jun 30, 2022 | 90.78 Mn |
| Mar 31, 2022 | 202.86 Mn |
| Dec 31, 2021 | 188.27 Mn |
| Sep 30, 2021 | 15.00 Mn |
| Jun 30, 2021 | 10.00 Mn |
| Mar 31, 2021 | 5.00 Mn |
| Mar 31, 2013 | 100,000.00 |
| Dec 31, 2011 | 2.15 Mn |